Table 1 Patient information of EOC cohorts
Variables | Non-carcinoma | Carcinoma | ||||
|---|---|---|---|---|---|---|
Normal (N = 33) | Benign (N = 44) | Borderline (N = 31) | PDS-EOC (N = 555) | RLP-EOC (N = 124) | NACT-EOC (N = 74) | |
Age—year | ||||||
Mean ± SD. | 52.0 ± 9.4 | 45.6 ± 16.4 | 45.4 ± 14.4 | 53.5 ± 9.3 | 53.6 ± 8.6 | 54.2 ± 9.0 |
Median (IQR) | 52.0 (49.0–55.0) | 45.0 (35.0–59.2) | 43.0 (35.0–58.0) | 53.0 (47.0–60.0) | 53.0 (48.0–59.2) | 56.5 (46.0–59.8) |
Range | 18–68 | 16–87 | 22–77 | 23–80 | 32–76 | 36–77 |
Histology—no. (%) | ||||||
HGSOC | 445 (80.2) | 121 (97.6) | 74 (100.0) | |||
LGSOC | 19 (3.4) | 1 (0.8) | 0 (0.0) | |||
CCOC | 38 (6.8) | 0 (0.0) | 0 (0.0) | |||
EMOC | 39 (7.0) | 2 (1.6) | 0 (0.0) | |||
MCOC | 14 (2.5) | 0 (0.0) | 0 (0.0) | |||
FIGO stage—no. (%) | ||||||
I | 44 (7.9) | 0 (0.0) | ||||
II | 62 (11.2) | 2 (2.7) | ||||
III | 373 (67.2) | 43 (58.1) | ||||
IV | 76 (13.7) | 29 (39.2) | ||||
Residual tumor—no. (%) | ||||||
No residual | 310 (55.8) | 97 (78.2) | 38 (51.4) | |||
Less than 1 cm | 182 (32.8) | 19 (15.3) | 29 (39.2) | |||
Greater than 1 cm | 62 (11.2) | 5 (4.0) | 7 (9.4) | |||
NA | 1 (0.2) | 3 (2.4) | 0 (0.0) | |||
Lymphatic metastasis—no. (%) | ||||||
Yes | 297 (53.5) | 67 (54.0) | 42 (56.8) | |||
No | 209 (37.6) | 21 (16.9) | 23 (31.1) | |||
NA | 49 (8.8) | 36 (29.0) | 9 (12.2) | |||
Frequency of chemotherapy—no. (%) | ||||||
0–2 | 32 (5.8) | 4 (3.2) | 0 (0.0) | |||
3–5 | 40 (7.2) | 26 (21.0) | 4 (5.4) | |||
6–8 | 478 (86.1) | 85 (68.5) | 62 (83.8) | |||
>8 | 5 (0.9) | 3 (2.4) | 8 (10.8) | |||
NA | 0 (0.0) | 6 (4.8) | 0 (0.0) | |||
Relapse-free survival—month | ||||||
Mean ± SD | 25.1 ± 23.7 | 14.4 ± 12.2 | 12.8 ± 14.4 | |||
Median (IQR) | 18.0 (9.0–34.0) | 10.0 (6.0–19.0) | 8.0 (5.0–13.0) | |||
Range | 1–154 | 1–80 | 1–89 | |||
